PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-2.44
Negative P/E while Biotechnology median is -5.96. Seth Klarman would scrutinize path to profitability versus peers.
No Data
No Data available this quarter, please select a different quarter.
4.52
P/B 1.25-1.5x Biotechnology median of 3.32. Guy Spier would scrutinize if premium reflects better asset utilization.
-11.55
Negative FCF while Biotechnology median P/FCF is -24.92. Seth Klarman would investigate cash flow improvement potential.
-11.55
Negative operating cash flow while Biotechnology median P/OCF is -25.57. Seth Klarman would investigate operational improvement potential.
4.52
Fair value ratio 1.25-1.5x Biotechnology median of 3.35. Guy Spier would scrutinize if premium reflects durable advantages.
-10.26%
Negative earnings while Biotechnology median yield is -2.38%. Seth Klarman would investigate path to profitability.
-8.66%
Negative FCF while Biotechnology median yield is -1.92%. Seth Klarman would investigate cash flow improvement potential.